Jon P. Stonehouse serves as the President, Chief Executive Officer, and Director at BioCryst Pharmaceuticals Inc., a role he has held since 2007. With a robust background in the pharmaceutical industry, Stonehouse has been instrumental in guiding BioCryst through significant growth and development. Prior to joining BioCryst, he held key leadership positions at various companies, including President and CEO of ZyStor Therapeutics, Inc., where he successfully led the company through its acquisition by BioMarin Pharmaceutical Inc. His career also includes a significant tenure at Merck & Co., Inc., where he held multiple roles in sales, marketing, and business development, showcasing his versatility and deep understanding of the industry. Under Stonehouse's leadership, BioCryst has made substantial strides in the development and commercialization of novel treatments for rare diseases. One of his notable achievements includes the successful FDA approval and launch of ORLADEYO® (berotralstat), a groundbreaking oral therapy for the prevention of hereditary angioedema (HAE) attacks. This milestone not only marked a significant advancement in the treatment landscape for HAE patients but also underscored Stonehouse's strategic vision and commitment to bringing innovative solutions to market. In his role as CEO, Stonehouse continues to steer BioCryst towards its mission of addressing unmet medical needs, leveraging his extensive experience to foster a culture of innovation and excellence within the company.